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Fibrosis (organ scarring) is a hallmark of many forms of
cardiovascular and renal disease, and causes organ
dysfunction and structural changes when normal tissue is
replaced with scar tissue; the accumulation of scar tissue
being a leading cause of death around the world. Despite
deep organ scarring potentially existing in many forms
(including myocardial and vascular sclerosis, renal interstitial
fibrosis, and glomerulosclerosis), current therapies have only
had limited success in delaying end-stage disease. The
peptide hormone relaxin is emerging as a potent antifibrotic
therapy with rapid-occurring efficacy. Recent studies have
demonstrated the antifibrotic actions of relaxin in
experimental models of cardiac and renal disease in vivo,
and the various levels at which relaxin acts to inhibit
fibroblast-induced collagen overproduction leading to
fibrosis, in vitro. Separate studies using relaxin gene-
knockout mice have demonstrated the significance of
endogenous relaxin as a naturally occurring and protective
moderator of collagen turnover, while the therapeutic
potential of relaxin has been enhanced by its ability to
promote vasodilation and renal hyperfiltration. This review
will summarize these coherent findings as a means of
highlighting the clinical potential of relaxin in cardiovascular
and renal disease.
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A growing body of evidence suggests that relaxin is both an
endogenous regulator of fibrosis and a potential antifibrotic
therapy for both developing and established fibrosis.
Relaxin is a small peptide hormone, structurally related to
the insulin family of peptides and is primarily produced by
the ovary and/or placenta in pregnancy and the prostate of
mammals.1,2 Humans (and higher primates) have three
relaxin genes, designated H1, H2, and H3 relaxin while
rodents have two genes, relaxin (equivalent to H2 relaxin)
and relaxin-3 (equivalent to H3 relaxin). H2 relaxin or
relaxin (in rodents) are the major source of circulating
relaxin, while the primary relaxin receptor was recently
identified as a G protein-coupled receptor, called the leucine-
rich repeat containing G protein-coupled receptor-7.3
Leucine-rich repeat containing G protein-coupled receptor-
7 is part of a subgroup (type C) of leucine-rich repeat
containing G protein-coupled receptors, that include recep-
tors for follicle-stimulating hormone, luteinizing hormone
and thyroid-stimulating hormone.2,3
Normally associated with reproduction, relaxin has been
implicated in a number of pregnancy-related functions
including softening the cervix and vagina at delivery.1,2
These actions are due in a large part to relaxin’s ability to
reduce collagen synthesis and increase collagen degradation
via stimulation of collagenase activity. It is now becoming
increasingly recognized that relaxin has a number of
functions outside reproduction, with numerous reports
suggesting therapeutic applications in non-reproductive
processes such as fibrosis, wound healing, cardiac protection,
and allergic responses.1,2,4 Not only are these actions
surprisingly diverse, but unlike its actions in reproductive
biology, occur in both males and females.
For the purposes of this review, we will concentrate on the
effect of relaxin on cardiovascular and renal disease (Table 1).
ANTIFIBROTIC EFFECTS OF RELAXIN
Functional significance of fibrosis
The disproportionate accumulation of extracellular matrix
(ECM), known as scarring or fibrosis is disfiguring and,
in the case of internal organs, life threatening. Renal scarring
is the final common pathway to all progressive renal disease,
manifesting itself in various forms affecting both the
renal parenchyma (tubulointerstitial fibrosis) and vascular
m i n i r e v i e w http://www.kidney-international.org
& 2006 International Society of Nephrology
Received 4 December 2005; revised 14 December 2005; accepted 21
December 2005; published online 1 March 2006
Correspondence: CS Samuel, Howard Florey Institute of Experimental
Physiology and Medicine, The University of Melbourne, Parkville, Victoria
3010, Australia. E-mail: c.samuel@hfi.unimelb.edu.au
1498 Kidney International (2006) 69, 1498–1502
structures (glomerulosclerosis and vascular sclerosis). The
etiology of cardiac fibrosis is similarly diverse, a consequence
of not only acute inflammation (postmyocardial infarct) but
also aging, increased hemodynamic load, neurohumoral
activation, and metabolic disorders. Cardiac fibrosis is in
particular the hallmark of hypertensive and ischemic heart
diseases. Accumulation of ECM, mainly fibrillar collagens,
increases tissue stiffness and impedes both contraction and
relaxation of the heart, leading to organ dysfunction.
In both cardiac and renal disease, damage depends
not only on the quantity of matrix produced (fibrogenesis),
but also the degree of its crosslinking and its reorganization,
or density. Fibrogenesis itself is dependent to a large extent
on the recruitment of myofibroblasts, cells with the
phenotypic features of both fibroblasts and vascular smooth
muscle. Recognized by their de novo expression of a
smooth muscle actin, myofibroblasts are prodigious produ-
cers of the ECM and are influenced by several mediators,
including cytokines, chemokines and growth factors.5
Furthermore, the newly synthesized matrix is remodelled by
various proteases, of which the matrix metalloproteinase
(MMP) family is one of the most important,5 with the
balance between fibrotic and antifibrotic signals determining
the extent of scarring.
Endogenous relaxin
While the kidney and heart have certain capacity to
regenerate from acute injury, so-called healing, chronic renal,
and myocardial disease results in irreversible scarring. The
biology of healing and scarring are similar, with the transition
between the two poorly understood. Increasingly, we
recognize that there are a number of naturally occurring
antifibrotic factors that are required to maintain homeostasis.
Relaxin may be one such molecule. In the same way that
hepatocyte growth factor and bone morphogenic protein-7
downregulate transforming growth factor-beta1 (TGF-b1)
signalling by interfering with Smad signal transduction,
relaxin also moderates fibrogenesis at several levels, by
inhibiting the influence of several profibrotic factors,
inhibiting fibroblast proliferation and/or differentiation,
and stimulating MMP-induced matrix degradation (reviewed
in Sherwood,1 Bathgate et al.,2 and Samuel et al.4).
Definitive evidence for the importance of endogenous
relaxin in regulating this process has been provided by studies
of the natural development of relaxin-deficient (RLX/)
mice. Male RLX/ mice developed an age-related progres-
sive fibrosis in several tissues, including the kidney6 and
heart.7 By 12 months of age, the kidney collagen concentra-
tion of male RLX/ mice was 25–30% greater than levels
measured in wild-type (RLXþ /þ ) animals,6 resulting in
increased cortical thickening, focal increases in interstitial
fibrosis, a general diffuse increase in glomerular matrix, and
renal dysfunction. An age-dependent increase in left
ventricular collagen content and concentration was also
more pronounced in RLX/ mice than RLXþ /þ
littermates.7 These findings were associated with increased
atrial hypertophy, left ventricular procollagen I mRNA
expression, chamber stiffness, and diastolic dysfunction in
RLX/ mice from 9 months of age and onwards. These
differences were however gender specific, with no such
phenotype in female RLX/ mice. Although the reason for
this is unclear, current interest is focused on the potential
compensatory role of other gender-specific hormones.
Local relaxin expression
Relaxin and/or relaxin-3 gene transcripts have been identified
by RT-PCR in the rodent atria and ventricles of the heart7–9
and the medulla and cortex of the kidney,6 with immuno-
histochemistry confirming local renal expression (Figure 1).
Furthermore, high-affinity binding sites for relaxin have been
identified in the cardiac atrium of male and female rats.10
These combined findings suggest that the heart and kidneys
are both potential sources and/or target organs for relaxin.
Despite the similarity between relaxin’s actions in the heart
Table 1 | Summary of the main effects of relaxin in the heart
and kidney
Tissue Actions/effects References
Heart Antifibrotic 1,2,4,7,8,15
Chronotropic 1,2,4
Inotropic 1,2,4,9
Vasodilatory 1,2,4,11,22,25
Angiogenic 1,2,4,24,25
Wound healing 1,2,4,24,25
Cardioprotective 1,2,4
Kidney Antifibrotic 1,2,4,6,12–17
Vasodilatory/renal hyperfiltration 1,2,4,19–21,23
a
b c
Figure 1 | Relaxin immunostaining in the rat kidney. Distribution
of relaxin immunostaining at (a) low- and (b) high-power
magnification, in the renal cortex of rats subjected to unilateral
ureteric obstruction. Relaxin immunostaining was detected with
the rabbit anti-rat serum 267-5 (kindly provided by Professor
O David Sherwood, University of Illinois at Urbana Champaign,
Urbana, IL, USA). (c) Also shown is the same kidney with non-immune
serum. Bars show relative magnification.
Kidney International (2006) 69, 1498–1502 1499
CS Samuel and TD Hewitson: Relaxin in cardiovascular and renal disease m i n i r e v i e w
and kidney though, potentially important differences exist.
Both H1 and H2 relaxin are constitutively expressed in
cardiovascular tissues and upregulated in the right atria and
left ventricles of patients with congestive heart failure, with
the plasma levels of relaxin increasing with severity of
disease.11 Similarly, increased relaxin-3 expression was
detected in the rat heart, following myocardial infarction.9
Conversely, relaxin mRNA expression is downregulated in the
kidney after unilateral ureteric obstruction (unpublished
observations). However, controversy surrounds the role and
significance of local relaxin synthesis.
Exogenous relaxin
A parallel, but in many ways quite distinct area of research, is
the effect of exogenous relaxin. Such work has concentrated
on exploring relaxin as a potential antifibrotic therapy.
Relaxin has repeatedly been shown to inhibit excessive
collagen accumulation in various cell culture and animal
models of fibrosis (reviewed in Sherwood,1 Bathgate et al.,2
and Samuel et al.4), ostensively a function of both its ability
to decrease collagen synthesis and increase its degradation.
The production of recombinant relaxin has been a major
advance in relaxin biology, providing the opportunity to
undertake a number of interventionist studies. Human
recombinant relaxin (H2 relaxin) is biologically active in
rodents, and has formed the basis of most in vitro and in vivo
studies. A number of recent in vivo studies have now clearly
shown that exogenous relaxin is able to moderate the
progression of disease in several experimental rodent models
of renal fibrosis.6,12–15 Continuous 2- to 4-week-infusion of
relaxin with osmotic minipumps was shown to ameliorate
fibrosis in several animal models. Morphometric studies in a
rat model of bromoethylamine-induced renal papillary
necrosis demonstrated that 28 days of H2 relaxin infusion
decreased the fractional area of interstitial collagen staining
by 75%. This was associated with a parallel reduction in
immunoreactive TGFb1, macrophage infiltration and a
preservation of glomerular filtration rate.12 Similar effects
were seen in both ablative and infarction models of 5/6
nephrectomy. There was a decrease in hypertension in the
infarction model, but no change in blood pressure in the
normotensive ablation model, suggesting that the preserva-
tion of glomerular filtration rate may be both blood pressure
dependent and independent.13 Likewise, relaxin decreased
focal glomerulosclerosis and interstitial fibrosis in an
antiglomerular basement membrane nephritis model of
disease.14
While a means of preventing fibrogenesis is important, the
ability to remove established fibrosis represents the ‘holy
grail.’ The clinical reality is that many renal patients present
with chronic disease, and therefore, established fibrosis.
Again, studies of the natural history of RLX/ mice have
provided valuable insights. Treatment of established renal6
and cardiac8 fibrosis in 12-month-old RLX/ mice for only
2 weeks with recombinant H2 RLX successfully reduced
collagen deposition, albeit to levels still greater than that seen
in RLXþ /þ mice (Figure 2). Infusion of recombinant H2
relaxin for a period of 14 days also reversed cardiac fibrosis by
58% in transgenic animals overexpressing b2 adrenergic
receptors,8 which ultimately undergo heart failure. Studies of
relaxin in the spontaneously hypertensive rat15 integrate
cardiovascular and renal work well, with these studies
showing that short-term perfusion of exogenous relaxin also
ameliorated established fibrosis. Administration of H2
relaxin to 9- to 10-month-old spontaneously hypertensive
rats led to a significant decrease in the collagen content
within the left ventricular myocardium and kidney, but did
not effect collagen in the unaffected chambers of the heart
(including the right ventricle and atria). These combined
studies therefore suggest that relaxin is an endogenous
protective factor in the heart and kidney, having the potential
to limit fibrogenesis, while exogenous relaxin has potent
antifibrotic properties.
Mechanism of relaxin’s antifibrotic properties in vitro studies
The ability of relaxin to downregulate collagen production
and increase collagen-degradation is central to its physio-
logical role. How it achieves this is however less clear. In vitro
studies probably provide the best insights into this process.
H2 relaxin acts directly on TGF-b1-stimulated renal fibro-
blasts to decrease myofibroblast differentiation16 and collagen
secretion by rat16 and human17 cells while increasing
expression of the interstitial collagen degrading enzyme,
MMP-13, the rat homologue of MMP-1.16 Using gelatin
zymography, Heeg et al.17 also reported a relaxin-induced
significant increase in MMP-2 secretion, with a smaller more
variable effect on MMP-9. However, the in vivo benefits of
increased MMP-2 activity may be ambiguous, as MMP-2
degradation of tubular basement membranes is an important
part of epithelial–mesenchymal transition, a major source of
fibroblasts in renal disease.18 The effect of relaxin on renal
scarring is not confined to the collagen constituents of the
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Figure 2 | (a) Relaxin decreases established cardiac and (b) renal
fibrosis in relaxin-deficient mice. Collagen concentration (collagen
content/dry weight (a)8 left ventricular or (b)6 kidney tissue) was
determined from 12-month-old relaxin wild-type (RLXþ /þ ), relaxin
knockout (RLX/) mice (with established fibrosis) treated with
vehicle alone or RLX/ mice treated with 0.5 mg/kg/day H2 relaxin
for a 14-day period. Numbers in parenthesis represent the number of
animals used per group. *Po0.05 compared with respective values
from RLXþ /þ mice. wPo0.05 compared with respective values from
RLX/ mice treated with vehicle alone.
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ECM, with H2 relaxin inhibiting fibronectin expression in
fibroblasts,14,17 tubular,14 and mesangial cell cultures,14
presumed to be through an increase in ubiquitin-dependent
degradation rather than a reduction in fibronectin mRNA.14
Conversely, studies of renal fibroblast kinetics have reported
that relaxin has little17 if any16 effect on fetal calf serum-
stimulated mitogenesis.
Cardiac fibroblasts and myofibroblasts are likewise the
cellular basis of ECM synthesis and remodelling in the heart.
Relaxin abrogated TGF-b1 and angiotensin II-stimulated
fibroblast proliferation, a smooth muscle actin expression,
collagen synthesis and deposition in neonatal (atrial and
ventricular) cardiac fibroblasts, which along with cardio-
myocytes, naturally express the leucine-rich repeat containing
G protein-coupled receptor-7 receptor.8 Additionally, both
latent and active forms of MMP-2 were increased (60 and
25%, respectively), once again with no marked effect on
MMP-9 expression.8 A consistent in vitro finding is therefore
that relaxin often only affects TGFb1 stimulated and not
basal fibrogenesis in these cells.
Recent studies in renal fibroblasts suggested that the
effects of relaxin were mediated to a large extent by the Smad
pathway.17 Phosphorylation of Smad2 and 3, formation of
complexes with Smad4, and translocation of these complexes
from the cytosol to the nucleus are key events in TGFb1
signalling. Relaxin inhibited the phosphorylation and trans-
location of Smad2 to the nucleus, in the absence of any effects
on phosphorylation of Smad3, c-Jun NH2-terminal kinase
1/2, extracellular signal-regulated protein kinase, or p3MAP
kinase.17 These findings therefore raise the possibility that
relaxin may lower collagen overexpression in affected organs
without affecting basal expression in unaffected tissues,
making it a highly desirable therapeutic agent for prevention
of aberrant fibrosis. It is important to note that while several
actions of relaxin are consistently identified in multiple
organs, some of its actions are tissue specific or vary between
organs, suggesting that relaxin inhibits fibrosis through
common and specific mechanisms, depending on the organ
it is applied to.
HEMODYNAMIC EFFECTS OF RELAXIN
In addition to its well-documented antifibrotic actions in the
kidney and heart, relaxin plays a number of other roles in
these organs, highlighting its diverse, but related protective
effects.
While the kidney and other vascular organs are known to
dilate during pregnancy, the factor(s) responsible for this
dilation were poorly understood, until Conrad and
co-workers elucidated that relaxin was the hormone involved
in renal vasodilation and hyperfiltration.19 H2 relaxin was
shown to increase effective renal plasma flow and glomerular
filtration rate, attenuate the renal circulatory response to
angiotensin II and reduce plasma osmolality regardless of
gender.19 Relaxin was also shown to reduce the myogenic
reactivity of small renal arteries of both pregnant20 and
conscious non-pregnant21 rats in vivo, while dilating small
and large arteries of several reproductive and non-reproduc-
tive organs in vitro, leading to decreased blood pressure and
increased coronary,22 renal, and uterine blood flow. These
relaxin-induced effects were biphasic, whereby low doses
were associated with vasodilation and a reduction in plasma
osmolality, while high doses were relatively inactive.19,21
Furthermore, both human and porcine relaxin were able to
potently antagonize renal and cardiac vasoconstriction in
response to endothelin (ET)-1 and angiotensin II,11,19 an
effect seen in mesenteric vessels of spontaneously hyperten-
sive rats, bovine aorta smooth muscle cells and rat coronary
endothelial cells.
From these combined findings, it has been hypothesized
that relaxin may induce its hemodynamic effects in the
cardiovascular and renal systems via a number of possible
mechanisms. Firstly, relaxin has repeatedly been shown to
stimulate coronary flow,22 renal vasodilation and hyperfiltra-
tion19 by increasing nitric oxide (NO) production, via
stimulation of nitric oxide synthase (NOS). This action was
blocked by nitric oxide synthase inhibitors, suggesting a NO-
dependent mechanism. Secondly, relaxin’s actions on ET were
thought to be mediated through the ETB receptor subtype, as
it was this receptor subtype that was specifically involved in
ET-induced stimulation of intracellular calcium in endothe-
lial cells, prostacyclin and NO.19 An essential role for the
endothelial ETB receptor subtype in the renal vasodilation,
hyperfiltration and reduced myogenic reactivity of small
renal arteries was initially established in relaxin-treated rats.19
However, controversy surrounds whether relaxin directly
stimulates the ETB receptor. While Conrad and co-workers
did not detect a relaxin-induced upregulation of ETB
receptor protein expression,23 they were able to demonstrate
that a relaxin-induced increase in vascular gelatinase (MMP-
2) activation led to the processing of ET-1 to ET1-32,24
thereby stimulating the ETB receptor and NO production in
rat renal vessels/vasculature. Furthermore, renal vasodilation
and hyperfiltration were completely blocked in relaxin-
treated rats by a specific peptide inhibitor of the gelatinases.24
In separate studies though, Dschietzig et al.25 were able to
report a relaxin-induced upregulation of ETB receptor
expression in human and bovine cell types in vitro and in
rat thoracic aortas, renal and mesenteric arteries ex vivo.
Thus, from both studies24,25 it was concluded that relaxin was
able to mediate its vasodilatory effects via regulation of the
ETB receptor (either directly or indirectly) and increased NO
production.
OTHER EFFECTS OF RELAXIN
In addition to its actions detailed above, relaxin has also been
shown to have other important roles in the heart and kidney,
confirming that these organs are targets for relaxin binding
and activity. Relaxin induces potent, direct and concentration-
dependent chronotropic and ionotropic effects in the rat heart
(reviewed in Sherwood,1 Bathgate et al.,2 and Samuel et al.4).
The relaxin-induced increase in heart rate has been demon-
strated in vivo, in spontaneously hypertensive rats15 and
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ex vivo in the isolated perfused intact heart, left and right
atria, and ventricular tissue. However, relaxin failed to induce
a chronotropic effect in the human heart,4 questioning the
significance of this effect in non-rodent species. In separate
studies, relaxin has been reported to stimulate angiogenesis
and wound healing, by stimulating new blood vessel
formation, enhanced granulation tissue formation and
increased vascular endothelial growth factor and basic
fibroblast growth factor expression at wound sites in a rat
myocardial infarct model.26 These findings demonstrated
that relaxin was able to increase the vascular supply to
injured tissues, resulting in increased wound healing
(reviewed in Sherwood,1 Bathgate et al.,2 and Samuel
et al.4). Relaxin has also been shown to counteract myocardial
damage induced by ischemia reperfusion, by increasing
coronary flow and NO production, while decreasing calcium
overload and infiltration of inflammatory cells.27
SUMMARY AND CONCLUSIONS
Relaxin is able to induce its effects via common and organ-
specific mechanisms, primarily involving the inhibition of
the influence of profibrotic factors, fibroblast differentiation
and collagen production in addition to an increase in MMP-
induced collagen degradation. However, despite its promise,
there are a number of key questions to be answered. Most of
our understanding of relaxin biology comes from studies in
rodents. Given the extent to which relaxin biology varies
among species, it is unclear how much of this applies to
humans. Furthermore, the significance of relaxin expression
at secondary sources, and that of its receptor, is controversial,
but is becoming increasingly studied, while the requirement
for continuous infusion of the hormone continues to remain
a major clinical obstacle.
Not withstanding the above problems, the use of a
naturally occurring inhibitor of fibrosis, with a well-
documented ability to remove established collagen, albeit in
animals models, offers great potential. Studies of relaxin and
its receptor offer an exciting opportunity for us to better
understand the biology of both cardiovascular and renal
disease in general.
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